Prospective, multi-institutional surgical data collection in pediatric neuro-oncology remains limited despite substantial variation in operative and perioperative management across institutions. To address this, we are developing the NeuroPoint Alliance (NPA) Quality Outcomes Database (QOD) Pediatric Tumor Surgery Registry. Here, we used a modified Delphi process to define a core outcome set for the registry. A modified Delphi study was conducted among pediatric neurosurgeons serving as site principal investigators for the proposed registry. Candidate data elements were rated on a 9-point Likert scale. Consensus for inclusion was predefined as ≥70
BACKGROUND:Personal protective measures help prevent infection and disease transmission during health crises such as Coronavirus disease 2019 (COVID-19). Populations facing barriers to adhering to these measures are more vulnerable to the health crisis. This study investigated the association of social drivers of health (SDoH), self-efficacy, and adverse substance use behavior changes with ability to practice COVID-19 personal protective behaviors among persons who inject drugs (PWID) with hepatitis C virus (HCV) infection history. METHODS:This study used the Hepatitis C Real Options (HERO) study's COVID-19 survey data (n = 157). The association of inability to practice COVID-19 personal protective behaviors (hand washing, social distancing, etc.) with (a) SDoH difficulties (employment, housing, etc.); (b) adverse substance use behavior change (overdose, injecting behavior, etc.); and (c) self-efficacy was tested using logistic regression. RESULTS:Inability to practice any personal protective behaviors was more likely among those experiencing any vs. no SDoH difficulties [adjusted odds ratio (aOR) (95% confidence interval (CI))] = 4.57 (1.57, 16.40); p = 0.003] but less likely for those with higher overall self-efficacy [aOR (95% CI) = 0.55 (0.32, 0.93); p = 0.025] and self-efficacy for setting goals [aOR (95% CI) = 0.63 (0.40, 0.96); p = 0.031]. The association between adverse substance use behavior changes and the outcome was not significant. CONCLUSIONS:Greater SDoH difficulties and lower self-efficacy were associated with greater inability to practice COVID-19 personal protective behaviors. Interventions to meet SDoH-related challenges and increase self-efficacy could help encourage practice of personal protective behaviors and economically reduce disease burden during health crises.
Metabolic and bariatric surgery (MBS) is surgery on the gastrointestinal tract aimed at weight loss and resolution of metabolic disease. These surgeries can result in remission of diabetes, hypertension, and sleep apnea in many patients, and can prolong life expectancy by 5 to 9 years. Because of the proven benefits, the American Society for Metabolic and Bariatric Surgery recommends surgery for all patients with a body mass index of 35 kg/m2 or higher, except for patients with diabetes whose threshold is 30 kg/m2 regardless of prior nonsurgical weight loss efforts. For children 13 years and older, MBS is recommended and has not been shown to negatively affect height or develop- ment. The MBS procedures have a very low risk of surgical complications but require careful preoperative counseling due to the major long-term effect expected on lifestyle. Family physicians are well suited to discuss MBS as an option for appropriate patients, refer to a qualified center, and monitor patients postoperatively. Attention must be given to effects on diet, fertility, and mental health, and adjustments must be made for long-term medications. These surgeries should not be viewed as a last resort for only patients with severe obesity but as an effective intervention to consider early in the treatment of obesity, especially when complicated by metabolic conditions.
Rapidly detecting infectious diseases such as Covid-19 is essential to control outbreaks and treat patients early. However, no available screening method combines low cost, portability, speed (<20 min, ideally <5 min), and ultrasensitivity (e.g., <1 virus/μL): lateral flow assays are fast, portable, and inexpensive but insensitive, whereas ultrasensitive assays require centralized labs with long turnaround times. We recently developed an ultrasensitive immunoassay that captures, separates, and counts saliva biomarker molecules using buoyant microbubbles and magnetic microspheres, but the original assay took 55 minutes and was not readily deployable. Here, we redesigned the assay protocol and reader for emergency medicine and mobile care by streamlining the workflow, collecting saliva with larger swabs, filtering it through a 10 μm cap, and using larger microbubbles to accelerate flotation. A paramedic successfully ran the assay on the back of a parked medical van in 3.5 minutes (spit-to-results) while achieving a 1.3 fg/mL analytical detection limit for SARS-CoV-2 nucleocapsid protein (~0.04 virus1/μL). The assay remained positive across 9 orders of magnitude. We describe the challenges and opportunities ahead for point-of-care deployment. ### Competing Interest Statement Dr. Anker is a Scientific Advisor for Akadeum Life Sciences, the company that sells the buoyant microbubbles used in the BAM assay, which owns the rights to a patent describing buoyant and magnetic analyte labeling and detection (US Patent 10,724,930). All other authors declare no competing interests. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Approval was from the Institutional Review Board (IRB) of Clemson University (IRB2021-0703) and the Institutional Review Board of Prisma Health (Pro00100731) I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data generated or analyzed during this study are included in this published article and its supplementary information files or are available from the corresponding author upon reasonable request. COVID Testing Research Seed Grant Program from Clemson University Agilent Technologies Inc., Applications and Core Technology University Relations (ACT-UR), 4599 Clemson University Creative Inquiry and Summer UR programs, 1852 Prisma Health, https://ror.org/03n7vd314
Abstract Background Despite providing both maternal and neonatal benefits, breastfeeding rates remain lower than goal targets. Prior observational studies suggest group prenatal care (GPNC) increases breastfeeding initiation compared to individual prenatal care (IPNC), but few randomized controlled trials (RCTs) have examined how GPNC impacts breastfeeding knowledge and self‐efficacy. We aimed to determine if participating in GPNC impacts breastfeeding knowledge, breastfeeding self‐efficacy, and breastfeeding prevalence postpartum. Materials and methods This is a planned secondary analysis of the Centering and Racial Disparities (CRADLE) RCT comparing the impact of GPNC versus IPNC on preterm birth. The CRADLE trial enrolled 2350 participants and randomized them to GPNC or IPNC. Eligibility requirements included age of 14–45 years, singleton pregnancy, entering prenatal care before 21 weeks’ gestation, and low‐risk pregnancy by institutional standards. Questionnaires assessed breastfeeding knowledge (adapted from the Infant Feeding Practices II Survey) and self‐efficacy (adapted from Wells’ 20‐item Prenatal Breast‐feeding Self‐Efficacy Scale). A per‐compliance approach was used, including participants who attended at least five sessions in their assigned group. The primary outcome was breastfeeding at hospital discharge. Secondary outcomes were breastfeeding knowledge, breastfeeding self‐efficacy, and breastfeeding prevalence at the postpartum visit. Chi‐square, Students’ t‐test, and multivariable logistic regression were applied. Additionally, a sensitivity analysis was conducted among nulliparous participants. Results Of the 2350 participants in the CRADLE study, 1561 were included in this secondary analysis. Participants self‐identified as Black (38.3%), Hispanic (24.2%), White (36.2%), or another race and ethnicity (1.3%), and the majority were multiparous. GPNC participants reported higher rates of breastfeeding at hospital discharge compared to IPNC (72.8% IPNC vs. 78.2% GPNC; adjusted odds ratio [aOR], 1.32; 95% confidence interval [CI], 1.02–1.72). GPNC participants also had greater breastfeeding knowledge, scoring higher on the composite knowledge questionnaire (score 18.5, standard deviation [SD] 4.3) compared to IPNC participants (score 17.5, SD 4.4; p < 0.001). No differences were observed in self‐efficacy scores or postpartum breastfeeding rates between GPNC and IPNC participants. These findings were generally consistent for nulliparous participants; however, breastfeeding rate at hospital discharge did not differ between arms. Conclusion GPNC increased breastfeeding knowledge and breastfeeding at hospital discharge but not breastfeeding at the postpartum visit. These findings suggest that education alone may be insufficient to create long‐lasting changes in breastfeeding behavior.